Diabetes Mellitus Type 2 and Non-alcoholic Fatty Liver Disease. The Effects of Metformin

Main Article Content

V.I. Pankiv


Diabetes mellitus (DM) type 2 in clinical practice is often associated with non-alcoholic fatty liver disease (NAFLD), which has a number of clinical and morphological forms and develops in patients who do not abuse alcohol. The combination of DM type 2 and NAFLD is associated not only with a high risk of developing liver cirrhosis and hepatocellular carcinoma in these patients. Although all aspects of the etiology of NAFLD is not fully known, it is points to the role of insulin resistance in its development. This concept has facilitated a number of clinical studies using metformin as the insulin sensitizer in insulin-resistant patients with NAFLD. The findings emphasize the importance of metformin in the treatment of NAFLD in combination with a hypocaloric diet and the control of body weight. It is also reported about other tissue effects of metformin in NAFLD.

Article Details

How to Cite
Pankiv, V. “Diabetes Mellitus Type 2 and Non-Alcoholic Fatty Liver Disease. The Effects of Metformin”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), no. 5.53, June 2013, pp. 55-63, doi:10.22141/2224-0721.5.53.2013.84493.
Lecture for Physician


Кондратьева Л.В. Бигуаниды в терапии сахарного диабета / Под ред. А.С. Аметова. — М.: Планида, 2013. — 48 с.

Урбанович А.М. Неалкогольний стеатогепатит у пацієнтів із цукровим діабетом 2-го типу: сучасний погляд на проблему / А.М. Урбанович // Міжнародний ендокринологічний журнал. — 2009. — № 2 (20). — С. 38-42.

Nonalcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology, 2012.

Mazza A., Fruci B., Garinis G.A. et al. The role of metformin in the management of NAFLD // Experimental Diabetes Research. — 2012. — http://dx.doi.org/10.1155/2012/716404

Loria P., Lonardo A., Bellentani S. et al. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question // Nutrition Metabolism Cardiovascular Diseases. — 2007. — Vol. 17 (9). — P. 684-698.

Socha P., Horvath A., Vajro P. et al. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review // Journal of Pediatric Gastroenterology and Nutrition. — 2009. — Vol. 48 (5). — P. 587-596.

Hamaguchi M., Kojima T., Takeda N. et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease // Annals of Internal Medicine. — 2005. — Vol. 143 (10). — P. 722-728.

Tiniakos D.G., Vos M.B., Brunt E.M. Nonalcoholic fatty liver disease: pathology and pathogenesis // Annual Review of Pathology. — 2010. — Vol. 5. — P. 145-171.

Garinis G.A., Fruci B., Mazza A. et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study // International Journal of Obesity. — 2010. — Vol. 34 (8). — P. 1255-1264.

Stumvoll M., Nurjhan N., Perriello G. et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus // The New England Journal of Medicine. — 1995. — Vol. 333 (9). — P. 550-554.

Loomba R., Lutchman G., Kleiner D.E. et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis // Alimentary Pharmacology and Therapeutics. — 2009. — Vol. 29 (2). — P. 172-182.

Haukeland J.W., Konopski Z., Eggesbø H.B. et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial // Scandinavian Journal of Gastroenterology. — 2009. — Vol. 44 (7). — P. 853-860.

Nar A., Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease // Acta Diabetologica. — Vol. 46 (2). — P. 113-118.

Lavine J.E., Schwimmer J.B., Molleston J.P. et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design // Contemporary Clinical Trials. — 2010. — Vol. 31 (1). — P. 62-70.

Krakoff J., Clark J.M., Crandall J.P. et al. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program // Obesity. — 2010. — Vol. 18 (9). — P. 1762-1767.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 > >>